LRRC29 Inhibitors
WZB117 and Triciribine target metabolic and signaling pathways, respectively, which can have downstream effects on proteins regulated by these pathways, including LRRC29. These inhibitors act by altering the cellular environment or signaling mechanisms in which LRRC29 is involved. U0126, LY294002, and Rapamycin are examples of kinase inhibitors that can change the phosphorylation status of numerous proteins and signaling cascades that may intersect with LRRC29 function.
SB431542 and DAPT are specific pathway inhibitors that can modify the TGF-β and Notch signaling pathways, respectively, potentially altering processes that govern the regulation of LRRC29. Additionally, compounds like XAV-939 and BIX 01294, which inhibit Tankyrase and G9a respectively, represent molecules that can affect the Wnt/β-catenin pathway and epigenetic regulation mechanisms, possibly impacting LRRC29 expression patterns. Other chemicals such as ZM 447439, PD0332991, and Y-27632 target cell division and cytoskeletal dynamics, providing a broad range of mechanisms that can indirectly influence the role of LRRC29 in cellular processes.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wiskostatin | 253449-04-6 | sc-204399 sc-204399A sc-204399B sc-204399C | 1 mg 5 mg 25 mg 50 mg | $49.00 $124.00 $441.00 $828.00 | 4 | |
Glucose transporter 1 inhibitor; can reduce glucose uptake, potentially affecting LRRC29-associated metabolic pathways. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $104.00 $141.00 | 14 | |
AKT inhibitor; can decrease AKT signaling, potentially influencing LRRC29 which might be regulated by this pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
MEK inhibitor; can block ERK pathway, potentially affecting processes that regulate LRRC29. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
TGF-β receptor inhibitor; can alter TGF-β signaling, potentially impacting LRRC29-related pathways. | ||||||
DAPT | 208255-80-5 | sc-201315 sc-201315A sc-201315B sc-201315C | 5 mg 25 mg 100 mg 1 g | $40.00 $120.00 $480.00 $2141.00 | 47 | |
Notch signaling pathway inhibitor; can interfere with cell differentiation processes that may involve LRRC29. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
PI3K inhibitor; can inhibit PI3K/Akt signaling, potentially affecting LRRC29 regulation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
mTOR inhibitor; can inhibit mTOR signaling, potentially impacting protein synthesis pathways associated with LRRC29. | ||||||
XAV939 | 284028-89-3 | sc-296704 sc-296704A sc-296704B | 1 mg 5 mg 50 mg | $36.00 $117.00 $525.00 | 26 | |
Tankyrase inhibitor; can affect Wnt/β-catenin signaling, potentially influencing LRRC29's role in this pathway. | ||||||
BIX01294 hydrochloride | 1392399-03-9 | sc-293525 sc-293525A sc-293525B | 1 mg 5 mg 25 mg | $37.00 $112.00 $408.00 | ||
G9a histone methyltransferase inhibitor; can alter epigenetic regulation, potentially affecting LRRC29 gene expression. | ||||||
ZM-447439 | 331771-20-1 | sc-200696 sc-200696A | 1 mg 10 mg | $153.00 $356.00 | 15 | |
Aurora kinase inhibitor; can disrupt cell cycle progression, potentially influencing LRRC29's role in cell division. | ||||||